Treatment Algorithms: Non-Small Cell Lung Cancer - Molecular profiling will increasingly guide the choice of therapy

NEW YORK, Nov. 13, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Treatment Algorithms: Non-Small Cell Lung Cancer – Molecular profiling will increasingly guide the choice of therapy

http://www.reportlinker.com/p01037160/Treatment-Algorithms-Non-Small-Cell-Lung-Cancer-–--Molecular-profiling-will-increasingly-guide-the-choice-of-therapy.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Despite advances in treatment, non-small cell lung cancer (NSCLC) remains a disease of poor prognosis, with an overall 5-year survival rate of just over 15%. The treatment of NSCLC is characterized by a high level of unmet need, most notably in the setting of advanced or metastatic disease, where outcomes are poor.Disease overview assessing etiology, risk factors, symptoms and patient segmentationIn-depth analysis of most common treatment types according to stage at diagnosis and patient characteristicsAnalysis of physician prescribing trends in the six surveyed markets across all stages of diseaseAnalysis of possible future treatment trends with regard to targeted therapiesLate presentation leads to poor survival rates – Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more than 85% of all lung cancer cases. According to Datamonitor's survey, over 60% of NSCLC patients have advanced or metastatic disease at presentation across the seven major markets.The uptake of targeted therapies in the first-line setting varies among the seven major markets – For example, Avastin (bevacizumab; Genentech/Roche/Chugai) is used in 34% of patients in the US, but its uptake in Europe ranges from only 1% in the UK to 16% in Italy.Mutation testing will increasingly guide the selection of therapy – Drug developers are increasingly targeting niche molecularly defined patient populations. This was recently exemplified by the approval of Xalkori (crizotinib; Pfizer) for NSCLC patients positive for the EML4-ALK translocation, believed to occur in only 5% of NSCLC patients.Gain insight into the treatment strategies and prescribing trends of 129 physicians treating NSCLC across the seven major marketsExcel deliverable contains extensive treatment trees for each disease stage and country, including percentages and patient numbersAssess non-small cell lung cancer market potential by identifying where treatment options are not fulfilling patient needs

OVERVIEW

•Catalyst•Summary

EXECUTIVE SUMMARY

•Strategic scoping and focus•Datamonitor key findings

DISEASE DEFINITION AND DIAGNOSIS

•Disease definition - Non-small cell lung cancer is the most common type of lung cancer - Lung cancer is the leading cause of cancer-related death

•Etiology

- Tobacco smoke is the main risk factor for lung cancer

- Environmental factors may also influence lung cancer risk

- Current screening methods do not improve survival

•Symptoms•Prognosis - Late presentation and diagnosis contribute to poor survival rates

•Presentation and diagnosis - Asymptomatic nature of early-stage disease delays time to initial presentation

•Influences on diagnosis and treatment rates - "Be clear on cancer" campaign- "Tips from former smokers" campaign

•Referral patterns - Referral is dictated by stage at diagnosis and treatment approach

PATIENT SEGMENTATION

•Stage distribution - Extensive use of the American Joint Committee on Cancer TNM classification system

CURRENT TREATMENT OPTIONS •Overview of the available drugs

•Stage I–III - Treatment type

•Stage IV - Treatment and prescribing trends: first-line therapy- Treatment and prescribing trends: maintenance therapy - Treatment and prescribing trends: second-line therapy - Treatment and prescribing trends: third-line therapy

•Local relapse - Treatment and prescribing trends: local relapse

•Distant relapse - Treatment and prescribing trends: first-line therapy - Treatment and prescribing trends: second-line therapy - Treatment and prescribing trends: third-line therapy

•Future changes in therapy - Mutation testing will increasingly guide the choice of therapy

- Targeted therapies will continue to be the focus of drug development

- Companion diagnostics will be further integrated into drug development and clinical practice

BIBLIOGRAPHY

•Journal papers•Websites•Datamonitor reports•Other

APPENDIX

A•Physician data

TABLES

•Table: NSCLC 5-year survival rates, by stage at diagnosis, 2002–08•Table: Leading treatments for NSCLC across the seven major markets, 2012 •Table: Survey respondents across the seven major markets, by country and physician type, 2012

FIGURES

•Figure: Distribution of NSCLC patients by stage of disease in each of the seven major markets, 2012 •Figure: Top three therapeutic strategies used in the treatment of Stage IA–Stage IIIB NSCLC across the seven major markets, 2012•Figure: Uptake of neoadjuvant and adjuvant chemotherapy in patients with Stage IIIA disease whose treatment plan includes surgery and chemotherapy •Figure: Top three chemotherapy regimens used in the adjuvant treatment of Stage IIIA NSCLC in each of the seven major markets, 2012 •Figure: Top three chemotherapy regimens used in the neoadjuvant treatment of Stage IIIA NSCLC in each of the seven major markets, 2012 •Figure: Top three therapeutic strategies used in the treatment of Stage IV NSCLC in each of the seven major markets, 2012•Figure: Top three chemotherapy regimens used in the first-line treatment of Stage IV NSCLC in each of the seven major markets, 2012•Figure: Percentage of Stage IIIB–IV NSCLC patients who are tested for EGFR mutations, EML4-ALK gene rearrangements, and KRAS mutations in each of the seven major markets, 2012 •Figure: Uptake of the Avastin-carboplatin-paclitaxel regimen in the first-line treatment of Stage IV NSCLC in each of the seven major markets, 2012•Figure: Uptake of Tarceva and Iressa in the first-line treatment of Stage IV NSCLC in each of the seven major markets, 2012•Figure: Use of maintenance therapy in Stage IV NSCLC in each of the seven major markets, 2012•Figure: Top three maintenance therapies used in Stage IV NSCLC in each of the seven major markets, 2012•Figure: Percentage of Stage IV NSCLC patients receiving second- and third-line chemotherapy in each of the seven major markets, 2012 •Figure: Top three therapies used in the second-line treatment of Stage IV NSCLC in each of the seven major markets, 2012•Figure: Top three therapies used in the third-line treatment of Stage IV NSCLC in each of the seven major markets, 2012•Figure: Percentage of Stage I–IIIB NSCLC patients who relapse with local and distant disease in each of the seven major markets, 2012 •Figure: Top three therapeutic strategies used in the treatment of Stage I–IIIB NSCLC patients who relapse with local disease in each of the seven major markets, 2012•Figure: Top three therapeutic strategies used in the treatment of Stage I–IIIB NSCLC patients who relapse with distant disease in each of the seven major markets, 2012•Figure: Top three chemotherapy regimens used in the first-line treatment of Stage I–IIIB patients who relapse with distant disease in each of the seven major markets, 2012 •Figure: Percentage of distant relapse NSCLC patients receiving second- and third-line chemotherapy in each of the seven major markets, 2012 •Figure: Top three therapies used in the second-line treatment of distant relapse NSCLC patients in each of the seven major markets, 2012•Figure: Top three therapies used in the third-line treatment of distant relapse NSCLC patients in each of the seven major markets, 2012

Companies Mentioned Hutchison 3G UK Limited, Merck KGaA, Wiley-BlackwellTo order this report:Pathology Industry: Treatment Algorithms: Non-Small Cell Lung Cancer – Molecular profiling will increasingly guide the choice of therapy

Contact
Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

RELATED LINKS
http://www.reportlinker.com